CHRS
Price
$1.16
Change
-$0.02 (-1.69%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
137.15M
72 days until earnings call
IBO
Price
$0.58
Change
-$0.01 (-1.69%)
Updated
Aug 29, 04:58 PM (EDT)
Capitalization
7.1M
Interact to see
Advertisement

CHRS vs IBO

Header iconCHRS vs IBO Comparison
Open Charts CHRS vs IBOBanner chart's image
Coherus Oncology
Price$1.16
Change-$0.02 (-1.69%)
Volume$9.01K
Capitalization137.15M
Impact BioMedical
Price$0.58
Change-$0.01 (-1.69%)
Volume$300
Capitalization7.1M
CHRS vs IBO Comparison Chart in %
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IBO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. IBO commentary
Aug 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Buy and IBO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 30, 2025
Stock price -- (CHRS: $1.16 vs. IBO: $0.59)
Brand notoriety: CHRS and IBO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 35% vs. IBO: 12%
Market capitalization -- CHRS: $137.15M vs. IBO: $7.1M
CHRS [@Biotechnology] is valued at $137.15M. IBO’s [@Biotechnology] market capitalization is $7.1M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 1 FA rating(s) are green whileIBO’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 1 green, 4 red.
  • IBO’s FA Score: 0 green, 5 red.
According to our system of comparison, CHRS is a better buy in the long-term than IBO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 5 TA indicator(s) are bullish while IBO’s TA Score has 3 bullish TA indicator(s).

  • CHRS’s TA Score: 5 bullish, 4 bearish.
  • IBO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CHRS is a better buy in the short-term than IBO.

Price Growth

CHRS (@Biotechnology) experienced а -5.69% price change this week, while IBO (@Biotechnology) price change was -1.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +20.57%, and the average quarterly price growth was +29.45%.

Reported Earning Dates

CHRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHRS($137M) has a higher market cap than IBO($7.1M). IBO has higher P/E ratio than CHRS: IBO (8.10) vs CHRS (2.19). CHRS YTD gains are higher at: -15.942 vs. IBO (-59.486). CHRS has higher annual earnings (EBITDA): 88.2M vs. IBO (-36.25M). CHRS has more cash in the bank: 238M vs. IBO (624K). IBO has less debt than CHRS: IBO (22.4M) vs CHRS (41M). CHRS has higher revenues than IBO: CHRS (272M) vs IBO (7K).
CHRSIBOCHRS / IBO
Capitalization137M7.1M1,930%
EBITDA88.2M-36.25M-243%
Gain YTD-15.942-59.48627%
P/E Ratio2.198.1027%
Revenue272M7K3,885,714%
Total Cash238M624K38,141%
Total Debt41M22.4M183%
FUNDAMENTALS RATINGS
CHRS vs IBO: Fundamental Ratings
CHRS
IBO
OUTLOOK RATING
1..100
1417
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4665
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a30

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CHRS's Valuation (25) in the Biotechnology industry is somewhat better than the same rating for IBO (81) in the null industry. This means that CHRS’s stock grew somewhat faster than IBO’s over the last 12 months.

CHRS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IBO (100) in the null industry. This means that CHRS’s stock grew similarly to IBO’s over the last 12 months.

CHRS's SMR Rating (100) in the Biotechnology industry is in the same range as IBO (100) in the null industry. This means that CHRS’s stock grew similarly to IBO’s over the last 12 months.

CHRS's Price Growth Rating (46) in the Biotechnology industry is in the same range as IBO (65) in the null industry. This means that CHRS’s stock grew similarly to IBO’s over the last 12 months.

CHRS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IBO (100) in the null industry. This means that CHRS’s stock grew similarly to IBO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHRSIBO
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
60%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IBO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LGO1.560.06
+4.00%
Largo
BYON9.440.32
+3.51%
Beyond
TKO190.144.49
+2.42%
TKO Group Holdings
FFBC26.53-0.26
-0.97%
First Financial Bancorp
PMAX0.34-0.01
-3.77%
Powell Max Ltd

IBO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBO has been loosely correlated with ITOS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if IBO jumps, then ITOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBO
1D Price
Change %
IBO100%
+1.30%
ITOS - IBO
45%
Loosely correlated
+0.20%
BMRN - IBO
42%
Loosely correlated
-1.67%
LPCN - IBO
27%
Poorly correlated
-1.00%
ADAG - IBO
23%
Poorly correlated
+1.37%
CHRS - IBO
22%
Poorly correlated
+3.51%
More